OPRM1 A118G: Opioid Requirement for Surgery Protocol

If you've had surgery and needed more pain medication than expected, or felt pain medications weren't working effectively, your OPRM1 gene might explain why. The A118G variant (rs1799971) affects how your body responds to opioid pain medications, influencing both dosage requirements and pain control outcomes.

This guide explains the genetic mechanisms behind individual opioid response differences and provides evidence-based protocols for optimizing surgical pain management based on your OPRM1 genotype.

Understanding OPRM1 A118G and Opioid Response

The OPRM1 gene encodes the μ-opioid receptor, the primary target for morphine, oxycodone, fentanyl, and other opioid analgesics. The A118G variant (also called N40D or Asn40Asp) creates a single amino acid change at position 40 of the receptor protein.

Key genetic facts:

• AA genotype (wild-type): Two normal copies, standard receptor function
• AG genotype (heterozygous): One variant copy, moderately reduced receptor activity
• GG genotype (homozygous): Two variant copies, significantly reduced receptor binding

The G allele frequency varies by ancestry: approximately 15-20% in European populations, 40-50% in East Asian populations, and 1-5% in African populations.

How the variant affects opioid response:

Research shows the G allele reduces β-endorphin binding affinity by 2-3 fold and decreases receptor signaling efficiency. This translates to altered clinical responses across multiple dimensions:

• Analgesic efficacy: G carriers often require 20-40% higher opioid doses for equivalent pain relief
• Side effect profile: Different rates of nausea, sedation, and respiratory depression
• Addiction risk: Paradoxically, the G allele may confer protection against opioid use disorder
• Metabolism interaction: Effects may vary depending on CYP2D6 status (codeine/tramadol activation)

Understanding your OPRM1 status allows surgical teams to proactively adjust pain management strategies rather than discovering inadequate control post-operatively.

OPRM1 A118G Genotype-Specific Surgery Protocols

Protocol for AA Genotype (Standard Response)

Patients with AA genotype typically respond to opioids as expected in clinical trials and guidelines.

Pre-operative planning:

• Standard dosing protocols appropriate for body weight and procedure type
• No genotype-specific adjustments needed
• Consider multimodal analgesia regardless (NSAIDs, acetaminophen, regional blocks)
• Document baseline pain sensitivity and previous opioid experiences

Intra-operative management:

• Fentanyl induction: 1-2 mcg/kg IV
• Morphine PCA settings: 1mg bolus, 6-minute lockout, 30mg 4-hour limit
• Consider remifentanil infusion: 0.05-0.2 mcg/kg/min for longer procedures
• Monitor for standard side effects (respiratory depression, nausea)

Post-operative protocol:

• Initial: Morphine 0.05-0.1 mg/kg IV every 3-4 hours PRN
• Transition to oral: Oxycodone 5-10mg every 4-6 hours, or hydrocodone/acetaminophen 5/325mg
• Add scheduled acetaminophen 1000mg every 6 hours
• Consider gabapentin 300mg TID for neuropathic component
• Target pain scores ≤3/10 at rest, ≤5/10 with movement

Duration and tapering:

Major surgery typically requires 5-7 days of opioids with gradual reduction. Transition to non-opioid analgesics by day 10-14 for most procedures.

Protocol for AG Genotype (Intermediate Response)

Heterozygous carriers show variable responses with tendency toward higher opioid requirements.

Pre-operative planning:

• Anticipate 15-25% higher opioid needs compared to AA genotype
• Discuss genetic factor with patient to set realistic expectations
• Strongly emphasize multimodal analgesia with regional techniques
• Consider pre-emptive gabapentin 600mg evening before surgery

Intra-operative management:

• Fentanyl induction: 2-3 mcg/kg IV (increased from standard)
• Morphine PCA settings: 1.5mg bolus, 6-minute lockout, 40mg 4-hour limit
• Add ketamine low-dose infusion: 0.1-0.2 mg/kg/hr (opioid-sparing)
• Increased monitoring for breakthrough pain in recovery room

Post-operative protocol:

• Initial: Morphine 0.1-0.15 mg/kg IV every 3-4 hours PRN
• PCA preferred over PRN dosing for better control
• Oral transition: Oxycodone 10-15mg every 4 hours, or hydrocodone/acetaminophen 10/325mg
• Mandatory acetaminophen 1000mg every 6 hours (scheduled, not PRN)
• Add celecoxib 200mg BID or ibuprofen 600mg TID unless contraindicated
• Consider gabapentin 300-600mg TID for 2 weeks post-op

Adjustment triggers:

If pain scores remain >5/10 despite initial protocol:

• Increase opioid dose by 25-50% rather than adding additional frequency
• Rotate to different opioid (cross-tolerance may not be complete)
• Consider transdermal fentanyl patch 25-50 mcg/hr for stable baseline control
• Evaluate for inadequate regional block or surgical complications

Duration and tapering:

Plan for 7-10 days of full-dose opioids with slower taper (reduce by 20% every 3 days). May require up to 3 weeks for major procedures.

Protocol for GG Genotype (Reduced Response)

Homozygous G carriers typically require significantly higher opioid doses and benefit most from genotype-guided protocols.

Pre-operative planning:

• Expect 30-50% higher opioid requirements compared to AA genotype
• Mandatory multimodal analgesia with at least 3 different mechanism classes
• Consider regional anesthesia (epidural, nerve blocks) as primary analgesic strategy
• Pre-emptive gabapentin 600-900mg evening before surgery
• Discuss genetic resistance openly to prevent patient anxiety about "seeking behavior"

Intra-operative management:

• Fentanyl induction: 3-5 mcg/kg IV
• Morphine PCA settings: 2mg bolus, 6-minute lockout, 50mg 4-hour limit
• Add ketamine infusion: 0.2-0.4 mg/kg/hr intra-operatively, 0.1 mg/kg/hr post-op
• Consider dexmedetomidine adjunct: 0.2-0.7 mcg/kg/hr for opioid-sparing
• Maximize regional techniques (epidural, paravertebral block, TAP block depending on surgery)

Post-operative protocol:

• Initial: Morphine 0.15-0.2 mg/kg IV every 3 hours PRN, or morphine PCA
• Oral transition may require higher doses: Oxycodone 15-20mg every 4 hours
• Alternative: Consider transdermal fentanyl 50-75 mcg/hr patch for baseline coverage
• Mandatory scheduled adjuvants:
  • Acetaminophen 1000mg every 6 hours
  • Celecoxib 200mg BID (or ibuprofen 800mg TID)
  • Gabapentin 600mg TID (or pregabalin 150mg BID)
• Add lidocaine 5% patch to surgical site if appropriate
• Consider low-dose naltrexone 1-2mg at bedtime (paradoxically enhances opioid sensitivity)

Advanced strategies for refractory pain:

If standard escalation fails (pain >6/10 despite optimized regimen):

• Opioid rotation: Switch to hydromorphone (5-7x more potent than morphine) or methadone
• Buprenorphine consideration: Partial agonist with high receptor affinity may overcome resistance
• Ketamine burst: 0.5 mg/kg IV over 30 minutes once daily for 3 days
• Regional catheter: Continuous peripheral nerve block with ropivacaine 0.2% at 5-8 mL/hr
• Neuromodulation: TENS unit, acupuncture, or interventional pain consultation

Duration and tapering:

GG patients may require 10-14 days of full-dose opioids. Taper very gradually (reduce by 10-20% every 5 days) to prevent rebound pain. Total duration may extend to 4-6 weeks for major surgery.

Surgical Specialty-Specific Considerations

Orthopedic Surgery

Bone and joint procedures typically produce severe acute pain that highlights OPRM1 variant effects.

Total joint replacement (hip/knee):

• AG/GG patients benefit significantly from periarticular injection (bupivacaine + epinephrine + ketorolac)
• Consider continuous femoral nerve block for TKA in G carriers
• Scheduled duloxetine 30-60mg daily starting pre-op (proven efficacy in joint replacement pain)
• Extended-release opioids may provide better baseline control than immediate-release

Spinal surgery:

• G carriers at higher risk of chronic post-surgical pain (transition to long-term management)
• Intrathecal morphine 0.2-0.3mg at closure provides 24-hour analgesia (even in GG patients)
• Muscle relaxants (cyclobenzaprine, tizanidine) important adjuncts for spasm
• Plan for 6-week minimum opioid course with close follow-up

Abdominal Surgery

Laparoscopic procedures:

• Even minimally invasive surgery causes significant visceral pain
• AG/GG patients may report discrepancy between incision pain (manageable) and deep pain (severe)
• TAP block effectiveness not diminished by OPRM1 variants (local anesthetic mechanism)
• Consider low-dose ketamine infusion for first 24 hours (0.1 mg/kg/hr)

Open abdominal surgery:

• Thoracic epidural analgesia partially bypasses OPRM1 effects (primarily local anesthetic-based)
• If epidural not placed, G carriers may require IV PCA for 3-5 days post-op
• Alvimopan (Entereg) for post-op ileus prevention particularly important (higher opioid doses)
• Transition to oral extended-release opioids earlier rather than continuing IV

Cardiothoracic Surgery

CABG and valve procedures:

• G carriers may require higher fentanyl doses during cardiopulmonary bypass
• Consider adjunct dexmedetomidine to reduce total opioid exposure (cardiac benefits)
• Post-operative: Target-controlled analgesia may provide better titration than standard PCA
• Balance between pain control and early extubation goals

Thoracoscopic procedures:

• Paravertebral block highly effective regardless of genotype
• Intercostal nerve cryoablation option for G carriers at high risk of chronic pain
• Chest tube removal particularly painful event requiring proactive dosing

Gynecologic and Urologic Surgery

Hysterectomy, prostatectomy:

• Visceral pain component responds less well to opioids even in AA patients
• Maximize regional techniques (TAP block, intrathecal morphine)
• Consider scheduled NSAIDs for inflammatory/uterine cramping component
• G carriers may benefit from longer-acting formulations (fentanyl patch)

Multimodal Analgesia Strategies by OPRM1 Genotype

All patients benefit from multimodal approaches, but genetic context changes the balance between opioid and non-opioid strategies.

Acetaminophen:

• Mechanism independent of OPRM1 (COX-3/cannabinoid receptor effects)
• Dose: 1000mg every 6 hours (650mg if hepatic impairment)
• IV formulation (Ofirmev) provides faster onset for immediate post-op period
• Equally effective across all genotypes

NSAIDs/COX-2 Inhibitors:

• Critical for reducing opioid burden in AG/GG patients
• Celecoxib 200-400mg BID (lower bleeding/renal risk than traditional NSAIDs)
• Ketorolac 15-30mg IV every 6 hours for 48 hours maximum
• Monitor renal function, avoid in CKD or elderly patients
• Cardiovascular risk assessment needed for prolonged use

Gabapentinoids:

• Gabapentin 300-600mg TID or pregabalin 75-150mg BID
• Mechanism: Voltage-gated calcium channel blockade (independent of opioid receptors)
• Start pre-operatively for loading
• Particularly beneficial for procedures with neuropathic pain component
• GG patients may need higher doses (gabapentin up to 900mg TID)

NMDA Antagonists:

• Ketamine: Prevents central sensitization and opioid-induced hyperalgesia
• Intra-operative: 0.2-0.5 mg/kg bolus then 0.1-0.4 mg/kg/hr infusion
• Post-operative: Continue at lower rate (0.05-0.1 mg/kg/hr) for 24-48 hours
• Particularly valuable in GG patients to reduce total opioid requirement
• Monitor for psychotomimetic effects (rare at analgesic doses)

Regional Anesthesia:

• Local anesthetics work independently of OPRM1 variants
• Neuraxial techniques (spinal/epidural) provide equivalent analgesia across genotypes
• Peripheral nerve blocks increasingly important for G carriers
• Continuous catheters allow extended duration without systemic opioid escalation

Adjuvant Medications:

• Dexmedetomidine: Alpha-2 agonist with opioid-sparing effects, reduces delirium risk
• Lidocaine infusions: 1-2 mg/kg/hr intra-op, may continue 24 hours (visceral pain)
• Magnesium: 30-50 mg/kg bolus then 8-10 mg/kg/hr (NMDA antagonist effects)
• Duloxetine: SNRI effective for osteoarthritis pain (60mg daily starting pre-op)

Non-pharmacologic Interventions:

While mechanism is unclear, these approaches may provide adjunctive benefits:

• Cold therapy/cryotherapy to surgical site
• Transcutaneous electrical nerve stimulation (TENS)
• Guided imagery and relaxation techniques
• Music therapy (proven to reduce pain scores)
• Early mobilization and physical therapy

Opioid Selection and Rotation Based on OPRM1

Different opioids may show varying sensitivity to OPRM1 variants due to receptor binding profiles and active metabolite formation.

Morphine:

• Directly affected by OPRM1 variants (primary μ-receptor agonist)
• GG patients show 2-3 fold reduction in morphine sensitivity
• Active metabolite morphine-6-glucuronide also acts at μ-receptor
• First-line choice only for AA genotype

Hydromorphone:

• 5-7 times more potent than morphine
• May partially overcome OPRM1 resistance through higher receptor occupancy
• Less histamine release, fewer side effects than morphine
• Consider for AG/GG patients requiring high-dose morphine equivalent

Fentanyl:

• Short-acting, high-affinity μ-agonist
• Transdermal formulation provides stable plasma levels (good for GG baseline control)
• Patch dosing: 25-100 mcg/hr depending on previous opioid exposure
• Breakthrough pain still requires additional short-acting agent

Oxycodone:

• Partial activity at κ-opioid receptors (in addition to μ)
• May provide better analgesia in OPRM1 variant carriers due to multi-receptor activity
• Consider as first-line oral agent for AG/GG patients
• Extended-release formulation for baseline coverage

Tramadol:

• Dual mechanism: Weak μ-agonist + SNRI activity
• Requires CYP2D6 metabolism to active form (O-desmethyltramadol)
• OPRM1 GG patients with functional CYP2D6 may respond better than to pure μ-agonists
• Avoid in CYP2D6 poor metabolizers (no benefit, only side effects)

Buprenorphine:

• Partial μ-agonist with very high receptor binding affinity
• May overcome OPRM1 variant resistance through stronger receptor engagement
• Low-dose buprenorphine (5-20 mcg/hr patch) increasingly used for post-surgical pain
• Requires specialized prescriber knowledge

Methadone:

• Long half-life, NMDA antagonist activity in addition to μ-agonism
• Unpredictable pharmacokinetics require specialist management
• Consider for GG patients with refractory chronic post-surgical pain
• Risk of QT prolongation necessitates ECG monitoring

Rotation strategy for inadequate control:

1. Calculate morphine milligram equivalents (MME) of current regimen
2. Select alternative opioid and reduce dose by 25-50% (incomplete cross-tolerance)
3. For GG patients, consider switching to opioid with broader receptor profile (oxycodone, tramadol)
4. Maintain stable non-opioid adjuvants during rotation
5. Reassess after 24-48 hours and adjust

CYP2D6 and OPRM1 Interaction Effects

Codeine and tramadol require CYP2D6 enzyme activation to produce analgesic effects, creating important pharmacogenetic interactions.

OPRM1 AA + CYP2D6 normal metabolizer:

• Codeine and tramadol work as expected
• Standard dosing protocols appropriate
• These agents remain reasonable options

OPRM1 AG/GG + CYP2D6 normal metabolizer:

• Codeine/tramadol may provide limited benefit
• Even with normal activation, reduced receptor response limits efficacy
• Choose alternative opioids (oxycodone, hydromorphone)

OPRM1 AA/AG + CYP2D6 poor metabolizer:

• Codeine and tramadol ineffective (no active metabolite formation)
• Avoid these agents entirely
• Risk of side effects without analgesia

OPRM1 AA/AG + CYP2D6 ultrarapid metabolizer:

• Risk of excessive opioid effect from codeine/tramadol
• Potentially fatal respiratory depression (especially pediatric cases)
• Contraindicated in children and breastfeeding women

Clinical recommendation:

Given complexity of interactions, many institutions now avoid codeine entirely. Tramadol may still have utility in AG/GG patients with normal CYP2D6 due to SNRI component providing non-opioid analgesia.

Chat about your pain genetics with Ask My DNA to discover how your OPRM1 and CYP2D6 genotypes interact to determine optimal opioid selection for your unique genetic profile.

Managing Opioid-Related Side Effects by Genotype

Side effect profiles may differ across OPRM1 genotypes due to varying receptor occupancy requirements and dose levels.

Nausea and vomiting:

• More common in AA patients (higher receptor activation at standard doses)
• AG/GG patients may experience less nausea but require anti-emetics if high doses needed
• Prevention: Ondansetron 4mg IV every 8 hours, or scopolamine patch
• Consider adding dexamethasone 4-8mg IV intra-operatively
• If persistent, consider opioid rotation or change administration route

Constipation:

• Universal across genotypes, proportional to total opioid dose
• GG patients at higher risk due to dose requirements
• Prevention (mandatory): Docusate 100mg BID + senna 2 tablets BID starting immediately
• Consider polyethylene glycol 17g daily if no bowel movement by day 3
• Peripherally-acting μ-opioid receptor antagonists (naloxegol, methylnaltrexone) for refractory cases

Sedation and cognitive effects:

• May be more pronounced in GG patients due to higher systemic opioid levels
• Balance pain control with functional recovery goals
• Stimulants (modafinil, methylphenidate) rarely indicated for post-surgical sedation
• Often improves with opioid rotation to agent with different CNS penetration

Respiratory depression:

• Risk exists across all genotypes, particularly with IV dosing
• Monitor oxygen saturation continuously for first 24 hours post-op
• Consider capnography monitoring in high-risk patients (sleep apnea, obesity)
• Naloxone 0.04-0.4mg IV reverses depression but also eliminates analgesia

Pruritus:

• Common with neuraxial opioids (spinal/epidural morphine)
• OPRM1 genotype effects on itching unclear
• Diphenhydramine 25-50mg IV/PO every 6 hours, or nalbuphine 5-10mg IV

Urinary retention:

• Frequency similar across genotypes
• Higher risk with neuraxial opioids and in men with prostatic hypertrophy
• May require temporary bladder catheterization
• Consider reducing opioid dose if no other cause identified

Chronic Pain Risk and Long-Term Outcomes

OPRM1 variants influence risk of transitioning from acute post-surgical to chronic pain.

Chronic post-surgical pain (CPSP) risk by genotype:

Studies show conflicting data, but emerging evidence suggests:

• AA genotype: Moderate baseline risk (10-30% depending on surgery type)
• AG genotype: Variable risk, may be slightly increased
• GG genotype: Potentially higher risk due to inadequate acute phase control and central sensitization

Risk factors for CPSP independent of genotype:

• Pre-existing chronic pain conditions
• Severe acute post-operative pain (>7/10 for >24 hours)
• Psychosocial factors (anxiety, depression, catastrophizing)
• Nerve injury during surgery
• Young age and female sex

Prevention strategies:

• Aggressive early pain control to prevent central sensitization (critical for GG patients)
• Pre-emptive gabapentinoids for surgeries with high nerve injury risk
• Ketamine infusions reduce CPSP incidence in high-risk procedures
• Early physical therapy and functional restoration
• Psychological support and anxiety management

Transition planning:

• By post-operative week 2-3, reassess need for continued opioids
• Identify patients at risk for prolonged use (pain scores not improving, increasing dose requirements)
• Taper schedule should be gradual (10-25% reduction every 5-7 days)
• Transition to non-opioid chronic pain management if pain persists beyond expected healing time
• Consider pain specialist referral if opioids required beyond 6-8 weeks

Opioid use disorder risk:

Interestingly, the OPRM1 G allele shows protective effects against opioid addiction in epidemiological studies. GG patients may experience less euphoria from opioids despite requiring higher analgesic doses.

However, any prolonged opioid use carries risk. Monitor for:

• Dose escalation beyond prescribed amounts
• Early refill requests
• Aberrant behaviors (seeking multiple providers)
• Functional impairment

Communication and Shared Decision-Making

Genetic information should enhance, not complicate, the patient-provider relationship.

Pre-operative discussion for AG/GG patients:

"Your genetic test shows a variant in the OPRM1 gene that affects how your body responds to pain medications like morphine and oxycodone. This means you may need higher doses than average to achieve good pain control after surgery. This is not unusual—about [15-50% depending on ancestry] of people have this variant.

We'll plan ahead by using multiple pain control methods, not just opioids. This includes nerve blocks, anti-inflammatory medications, and other techniques. We want you to know that if you need more pain medication, it's because of your genetics, not because you're doing anything wrong.

We'll work together to find the right combination to keep you comfortable while minimizing side effects."

Setting realistic expectations:

• Pain control goal: 3-4/10 at rest, 5-6/10 with activity (perfect zero often unrealistic)
• Timeline: Most surgical pain peaks days 2-3, should improve steadily by week 1-2
• Function over complete pain elimination: Ability to breathe deeply, walk, eat matters more than total numbness

Addressing concerns about opioid use:

• Emphasize time-limited nature of post-surgical opioids
• Explain protective effect of GG genotype against addiction
• Normalize higher dose requirements (genetic, not psychological)
• Provide clear tapering plan in advance

Documentation:

Include OPRM1 genotype in pre-operative assessment and anesthesia record. This ensures continuity if different providers manage post-operative care and prevents misinterpretation of high opioid requirements as drug-seeking behavior.

Clinical Evidence and Research Updates

Landmark studies:

• Klepstad et al. (2004): First demonstration of OPRM1 A118G effect on morphine dose requirements in cancer pain patients
• Sia et al. (2008): Meta-analysis showing 118G allele carriers require more morphine for post-operative analgesia
• Kolesnikov et al. (2011): GG patients show reduced morphine-induced analgesia but also reduced side effects
• Hwang et al. (2014): Asian population study confirming higher opioid requirements in G carriers post-cesarean section

Ongoing debates:

• Magnitude of effect varies significantly across studies (20-50% increased requirement)
• Some studies show no significant clinical difference
• Possible explanations: Ethnicity differences, study design, inadequate sample size, gene-gene interactions

Current clinical adoption:

Routine pre-operative OPRM1 testing is not yet standard practice in most institutions. However, knowledge of genotype from prior testing (consumer genetics, pain clinic panels) should be incorporated into perioperative planning.

Future directions:

• Polygenic risk scores incorporating multiple pain-related genes (COMT, CACNG2, GCH1)
• Integration with pharmacokinetic genes (CYP2D6, CYP3A4) for comprehensive opioid response prediction
• Development of genotype-specific clinical decision support tools
• Alternative mu-opioid receptor ligands with different pharmacogenetic profiles

Frequently Asked Questions

Should I get OPRM1 testing before elective surgery?

If you have a history of poor pain control with opioids, or previous surgery where you needed much higher doses than expected, OPRM1 testing could help your surgical team plan more effectively. However, it's not routinely recommended for all patients. If you already have genetic data from a consumer test (23andMe, AncestryDNA) or clinical panel, check if rs1799971 (A118G) is included—many panels test this variant.

If I'm a GG carrier, will I definitely need more opioids after surgery?

Not always. The genetic effect is significant but not absolute. About 60-70% of GG carriers require higher doses, but individual response varies based on surgery type, other genetic factors, pain sensitivity, and psychological factors. Your surgical team should plan for the possibility but adjust based on your actual response.

Can I use my 23andMe data to determine my OPRM1 status?

Yes, 23andMe and many other consumer genetic tests include rs1799971. Your raw data will show your genotype as AA, AG, or GG. Share this information with your anesthesiologist during pre-operative assessment so they can incorporate it into your pain management plan.

Does OPRM1 affect other medications besides opioids?

OPRM1 specifically affects mu-opioid receptor agonists (morphine, oxycodone, fentanyl, etc.). It does not affect NSAIDs (ibuprofen, celecoxib), acetaminophen, local anesthetics, or most other pain medications. This is why multimodal analgesia is so important—it utilizes multiple pathways that aren't dependent on this single genetic variant.

Conclusion

The OPRM1 A118G variant represents one of the most clinically relevant pharmacogenetic factors in perioperative pain management. While AA genotype patients respond to standard protocols, AG and especially GG carriers benefit significantly from proactive, genotype-informed approaches that anticipate higher opioid requirements and maximize multimodal analgesic strategies.

Key principles include early aggressive pain control to prevent central sensitization, preferential use of multimodal non-opioid techniques in G carriers, appropriate dose escalation without stigma, and careful monitoring for both inadequate analgesia and opioid-related side effects. By incorporating genetic information into perioperative planning, surgical teams can optimize pain control, improve patient satisfaction, reduce chronic pain risk, and facilitate faster functional recovery.

Educational Content Disclaimer

This article provides educational information about genetic variants and is not intended as medical advice. Always consult qualified healthcare providers for personalized medical guidance. Genetic information should be interpreted alongside medical history and professional assessment.